As Boron Neutron Capture Therapy (BNCT) radiation science is emerging as a hopeful method of curing cancer, Cosylab is enabling BNCT companies to bring it to everyday clinical practice and deliver better health care to patients worldwide. Cosylab recently partnered with Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT).
BNCT is a targeted radiation cancer therapy in which neutron beams destroy only boron compound-bearing tumors without destroying neighboring normal tissue.
Cosylab is a proven partner with over two decades of experience solving complex software challenges in radiation therapy. OncologyOne, Cosylab’s software suite of medical-grade products, supports a growing number of clinical and technical advancements in BNCT.
Cosylab and Neutron Therapeutics recently announced a strategic collaboration to incorporate Cosylab’s OncologyOne radiation therapy product suite into Neutron’s nuBeam® BNCT systems at hospitals worldwide.
“Neutron’s work to expand the reach and potential of BNCT is aligned with Cosylab’s dedication to improving radiation therapy at the highest level and providing advanced cancer care to patients,” said Mark Pleško, CEO of Cosylab. “We believe that, in sharing our software expertise, we can immensely improve the utility and capability of this novel therapeutic approach.”
The full press release is available here.